220 related articles for article (PubMed ID: 16952490)
1. Liver disease selectively modulates cytochrome P450--mediated metabolism.
Frye RF; Zgheib NK; Matzke GR; Chaves-Gnecco D; Rabinovitz M; Shaikh OS; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):235-45. PubMed ID: 16952490
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
3. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
4. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
5. Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Zgheib NK; Frye RF; Tracy TS; Romkes M; Branch RA
Clin Pharmacol Ther; 2006 Sep; 80(3):257-63. PubMed ID: 16952492
[TBL] [Abstract][Full Text] [Related]
6. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.
Adedoyin A; Frye RF; Mauro K; Branch RA
Br J Clin Pharmacol; 1998 Sep; 46(3):215-9. PubMed ID: 9764961
[TBL] [Abstract][Full Text] [Related]
8. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
9. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
11. Evaluation on activity of cytochrome p450 enzymes in turbot via a probe drug cocktail.
Chang ZQ; Li J; Zhai QQ
J Aquat Anim Health; 2014 Dec; 26(4):272-7. PubMed ID: 25369285
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence revisited: influence of age and sex on CYP enzymes.
Bebia Z; Buch SC; Wilson JW; Frye RF; Romkes M; Cecchetti A; Chaves-Gnecco D; Branch RA
Clin Pharmacol Ther; 2004 Dec; 76(6):618-27. PubMed ID: 15592333
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba.
Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Cui Y; Ang CY
Drugs Aging; 2005; 22(6):525-39. PubMed ID: 15974642
[TBL] [Abstract][Full Text] [Related]
14. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
15. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
16. A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution.
Stewart NA; Buch SC; Conrads TP; Branch RA
Analyst; 2011 Feb; 136(3):605-12. PubMed ID: 21107456
[TBL] [Abstract][Full Text] [Related]
17. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
Fuhr U; Jetter A; Kirchheiner J
Clin Pharmacol Ther; 2007 Feb; 81(2):270-83. PubMed ID: 17259951
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
[TBL] [Abstract][Full Text] [Related]
19. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.
Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Carrier J; Khan IA; Edwards DJ; Shah A
Clin Pharmacol Ther; 2004 Nov; 76(5):428-40. PubMed ID: 15536458
[TBL] [Abstract][Full Text] [Related]
20. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Asimus S; Elsherbiny D; Hai TN; Jansson B; Huong NV; Petzold MG; Simonsson US; Ashton M
Fundam Clin Pharmacol; 2007 Jun; 21(3):307-16. PubMed ID: 17521300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
